Skip to main content
  • Research article
  • Open access
  • Published:

Effects of BNT162b2 mRNA vaccine on COVID-19 infection and hospitalisation amongst older people: matched case control study for England



The BNT162b2 mRNA vaccine has been shown to be effective at preventing serious COVID-19 events in clinical trials. There is less evidence on effectiveness in real-world settings, especially for older people. Here, we aimed to estimate vaccine effectiveness in the context of the rapid NHS mass-vaccination programme in England, exploiting age-based vaccination eligibility thresholds to minimise and correct for selection bias.


We studied 170,226 individuals between the ages of 80 and 83 years from community settings outside care homes who received one dose of BNT162b2 mRNA between the 15 and 20 December 2020 and were scheduled a second dose 21 days later. We matched these vaccine recipients to slightly younger (aged 76–79 years) persons not yet eligible to receive the vaccine on gender, area of residence, area deprivation, health status, living arrangements, acute illness, and history of seasonal flu vaccination. We compared their rates of COVID-19 positivity and hospitalisation in the subsequent 45 days. We adjusted for the increasing concentration of COVID-19 positivity in the control population caused by the requirement to have no COVID-19 symptoms prior to vaccination.


Emergency hospital admissions were 51.0% (95% confidence interval 19.9 to 69.5%) lower and positive COVID-19 tests were 55.2% (40.8 to 66.8%) lower for vaccinated individuals compared to matched controls 21 to 27 days after first vaccination. Emergency admissions were 75.6% (52.8 to 87.6%) lower, and positive COVID-19 tests were 70.1% (55.1 to 80.1%) lower 35 to 41 days after first vaccination when 79% of participants had received a second dose within 26 days of their first dose.


Receipt of the BNT162b2 mRNA vaccine is effective at reducing COVID-19 hospitalisations and infections. The nationwide vaccination of older adults in England with the BNT162b2 mRNA vaccine reduced the burden of COVID-19.

Peer Review reports


Several vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (COVID-19) have been demonstrated to be safe and highly effective in phase 3 randomised clinical trials, with efficacy estimates for prevention of symptomatic disease ranging from 62 to 95% [1,2,3,4]. However, it is also important to examine their effectiveness when deployed in mass vaccination campaigns across diverse populations, where trial exclusion criteria do not apply and where deviations from dosing and handling protocols may occur.

Early evidence from a matched case-control study of mass vaccination using the BNT162b2 mRNA COVID-19 vaccine in Israel estimated real-world effectiveness consistent with reported trial efficacy [3, 5]. This indirectly provided evidence that vaccine effectiveness was maintained against the more transmissible B.1.1.7. (Alpha) variant [5, 6], which was widespread in the population during the study period. Vaccine effectiveness estimates were consistent across age groups, though they were slightly lower amongst people with multiple coexisting health conditions [5]. Similarly, estimates from Scotland [7] and England [8, 9] provide further early evidence of effectiveness. However, such non-randomised matching studies may be biased by systematic differences between intervention and control groups and between those receiving the intervention at different points in time. The remarkable speed of COVID-19 vaccination rollouts [5, 7,8,9] and specific prioritisation of vulnerable groups [10] heighten the risk of these biases, as acknowledged in existing studies [5, 7,8,9].

We exploit age-based eligibility phasing in the early stages of the nationwide National Health Service (NHS) population vaccination programme in England to estimate the real-world effectiveness of the BNT162b2 mRNA vaccine. We match vaccinated persons aged 80 to 83 years to slightly younger persons who did not become eligible for the vaccine until three weeks later and compare their rates of COVID-19 infection and hospitalisation over the 45 days following the date of their first dose. It is particularly important to assess real-world vaccine effectiveness in this older population group, because severe COVID-19 is strongly age-associated [11] and adaptive immune responses decline with age [12].



MW and JH obtained population-wide person-level data for England, including vaccination details (date, type and dose), SARS-CoV-2 tests (date, result), age, gender, area of residence, use of hospital services and dates of death. For data sources, linkage methods and access, see Appendix 1. Data were extracted on 9 February 2021 and include complete records to 3 February 2021.


We examined rates per 100,000 people for three outcomes: SARS-CoV-2 infection and COVID-19 related hospital attendances and hospitalisations. Infection was recorded by specimen date of SARS-CoV-2 positive polymerase chain reaction (PCR) test results from health care facilities (called Pillar 1 testing) or community testing (Pillar 2). COVID-19 related emergency department attendances were measured using diagnosis information from emergency department records combined with linked positive COVID-19 test results from 14 days before to 6 days after the attendance (see Appendix 3). COVID-19 related hospital admissions were measured using admitted patient care spell records available on discharge. The required information is available for 95% of all emergency department attendances and 93% of all emergency admissions.

Study design

The first phase of the NHS vaccination programme in England targeted: (1) front-line health and social care workers, (2) older care home residents and their carers, and (3) people aged 80 years and over [10]. Differences in risks of exposure and outcome within the first two groups are not effectively measured in administrative datasets. We therefore focused on 171,931 individuals aged 80–83 years not living in care homes that received their first dose between 15 and 20 December 2020, of whom 78.8% received a second dose within 26 days.

We compared vaccinated cases to slightly younger people aged 72–79 years who became eligible for vaccination later. The speed of vaccination rollout meant many of these received a first vaccine dose during the follow-up period (see Fig. 1). We identified suitable controls for each day of the follow-up period as those who had not received their first dose more than 2 weeks earlier. These individuals were not expected to have developed significant immunity from COVID-19 at the point they were used as controls. We then matched the vaccinated cases to the set of suitable controls separately for each day of the follow-up period.

Fig. 1
figure 1

Numbers of people in England who received their first COVID-19 vaccination dose between 8 December 2020 and 3 February 2021 by age group. The cumulative totals are relative to estimates of eligible population based on extracts from the National Health Application and Infrastructure Services (NHAIS) system as of the 15 November 2020. Prior to the 4 January 2021, all individuals received the BNT162b2 mRNA vaccine, after which individuals were vaccinated with either the BNT162b2 mRNA or ChAdOx1 adenovirus vector vaccines

A requirement for vaccination was that individuals should not have had a COVID-19 infection in the previous 2 weeks. Therefore, as the rollout of the vaccination progressed and the population available as potential controls reduced through vaccination, the group not yet vaccinated and available as potential controls contained a progressively higher proportion of people who tested positive for COVID-19. This selection process biases the rate of positive tests in the control group upwards and would artificially inflate estimated vaccine effectiveness. To correct for this bias, we sequentially adjusted event rates in the intervention and control groups so that they remained consistent in the first 11 days of follow-up. Appendix 2 documents the adjustment method used.

Matching and statistical analysis

Isolating the impact of vaccination requires a study design that accounts for temporal changes in infection rates, for which we used 1:1 exact matching [13] to account for several factors associated with exposure and outcomes: gender; area of residence [14]; small area deprivation [15]; ethnic group; health status; living arrangements; seasonal influenza vaccine history since April 2020; and emergency hospital stays in the previous 2 months. We excluded 1705 (1.0%) individuals with prior COVID-19 history to avoid likely pre-existing immunity [16, 17]. We excluded individuals from the control group if they were living in care homes or were not alive on the 15 December 2020. We dropped matched pairs where either individual was in hospital on the vaccination date or the pair lived at the same property (see Fig. 2).

Fig. 2
figure 2

Flow diagram of the study population with eligibility criteria, exclusions, and matching methodology

We matched vaccinated individuals to unique controls without replacement. We assigned a control randomly where multiple matches were available for a vaccinated individual. We repeated the matching process five times with different random number seeds to create five matched populations. We bootstrapped 100 samples with replacement from each of these five matched populations and obtained confidence intervals using percentile values from the 500 samples.

Tests of robustness

To explore the robustness of the adjustment for selection bias in the control group and the sensitivity of the results to the age group used for the controls, we compared the older age group to two different younger age groups. First, we matched vaccinated individuals aged 80–81 to controls aged 76–77 and vaccinated individuals aged 82–83 to controls aged 78–79. Second, we matched vaccinated individuals aged 80–81 to controls aged 72–73 and vaccinated individuals aged 82–83 to controls aged 74–75. The younger control group is less similar in age but unexposed to the vaccine for longer and therefore less prone to selection bias. We also tested the sensitivity of the results to reducing the inclusion criteria for eligible controls from 2 to 1-week post first vaccine dose (see Appendix 6). We used the STROBE (Strengthening The Reporting of OBservational Studies in Epidemiology) cohort checklist when writing our report [18].


Study population

Of the total 1,685,530 individuals aged 80–83, 170,226 met our inclusion criteria. They were not residents of care homes, had no prior history of COVID-19, and received a first dose of the BNT162b2 mRNA vaccine between 15 and 20 December 2020 (Fig. 2). Of these, we exact-matched 131,236 (77.1%) to control individuals aged 76–79 who were not yet eligible for vaccination (Figs. 1 and 2). The requirement for an exact match generated a matched study population with lower proportions of individuals who were frail or clinically extremely vulnerable, from minority ethnic groups, or from socially-deprived areas compared to the full study population (Table 1 and Appendix 4).

Table 1 Demographic and clinical characteristics of vaccinated persons and their unvaccinated controls based on the matched cohort at baseline (day 11 after vaccination)

Vaccine effectiveness

Across 45 days of follow-up, there was an average of 13.7 documented SARS-CoV-2 infections per day per 100,000 vaccinated individuals, compared to 23.2 per 100,000 unvaccinated controls. Over the same period, a daily average of 5.0 individuals per 100,000 attended an emergency department with COVID-19 and 5.3 per 100,000 were hospitalised with COVID-19 amongst the vaccinated cohort, compared to 9.6 per 100,000 (attended) and 9.4 per 100,000 (hospitalised) amongst unvaccinated controls.

For the unvaccinated comparison group, COVID-19 event rates increased in the first 2 weeks of follow-up, with documented infections reaching a maximum at day 20, and emergency hospital attendances and admissions peaking between days 23 and 26 (Fig. 3). These profiles reflect the shape of the COVID-19 pandemic in England where prevalence peaked around the 1 January 2021 [19], and hospitalisations peaked in the second week of January 2021 [20]. For the vaccinated group, documented infections peaked earlier (day 14) and hospitalisations peaked between days 23 and 26.

Fig. 3
figure 3

Profiles of positive COVID-19 infections, emergency department (A&E) attendances, and unplanned hospital admissions by days since first dose of vaccination. The data represent people aged between 80 to 83 years who received their first dose of the BNT162b2 mRNA COVID-19 vaccine between the 15 and 20 December 2020 with comparison to their matched controls. 95% confidence intervals are displayed as dashed lines

We found similar results when we matched vaccinated individuals to unvaccinated individuals aged 72–75 years and when the comparison group was restricted to individuals who remained unvaccinated throughout the follow-up period (see Appendix 6).

Table 2 shows vaccine effectiveness, defined as percentage difference between vaccinated and unvaccinated groups, for each outcome across four time periods. Effectiveness increased over the follow-up period for all three outcomes. Estimated effectiveness at 21–27 days was 55.2% (95% CI 40.8–66.8%) for documented infection, 57.8% (30.8–74.5%) for emergency hospital attendances, and 50.1% (19.9–69.5%) for admissions. By days 35–41, the estimated effectiveness was 70.1% (55.1–80.1%) for documented infection, 78.9% (60.0–89.9%) for emergency department attendances, and 75.6% (52.8–87.6%) for hospitalisations.

Table 2 Estimates of the effectiveness of the BNT162b2 mRNA COVID-19 vaccine by days since vaccination


We considered 171,931 individuals aged 80 to 83 years in England who received a first dose of BNT162b2 mRNA COVID-19 vaccine as part of the nationwide NHS vaccination campaign in England. We compared their rates of SARS-CoV-2 positive tests and COVID-19 hospitalisations in the subsequent 45 days to those for slightly younger individuals with the same characteristics who became eligible for vaccination later. Emergency admission was 50.1% (19.9 to 69.5%) less likely 21 to 27 days after vaccination and 75.6% (52.8 to 87.6%) less likely 35 to 41 days after first vaccination and 7 days after 80% had received their second dose. COVID-19 infection was 55.2% (40.8 to 66.8%) less likely 21 to 27 days after vaccination and 70.1% (55.1 to 80.1%) less likely 35 to 41 days after first vaccination and 7 days after 80% had received their second dose. Collectively, these results are consistent with one dose of the BNT162b2 mRNA vaccine reducing events from 14 days after vaccination, with more effectiveness in reducing the severity of symptoms than preventing infection.

Our results are broadly consistent with existing estimates of BNT162b vaccine effectiveness, despite variations in study design, participant demographics, and outcome definitions [21]. We estimate effectiveness against documented infection of approximately 55% 21–27 days after one dose, rising to 70% after the majority received a second dose. These estimates are relatively consistent with results from a similar studies in England (55% after one dose, 80% 7 days after all received a second dose) [8] and Scotland (78% 21–27 days after one dose) [7] and from the older age group in a similar study in Israel (50% after one dose, 95% 7 days after all received a second dose) [5]. These estimates are also comparable to estimates of vaccine effectiveness against documented infection in working-age adults in England (70% after one dose, 85% 7 days after second dose) [9] and to all-age results from a randomised controlled trial (52% rising to 95%) [3]. Our point estimate of effectiveness against hospitalisation with COVID-19 (76% 7 days after most received a second dose) is somewhat lower than, though statistically compatible with, other estimates (80–87%) [5, 8].

Several factors likely contribute to these differences. First, our estimates are specifically for an older population where vaccine-induced immune responses may be sub-optimal [12]. In addition, our population included 20% of vaccinated individuals for whom the second dose was extended beyond the study period. This may explain the greater agreement with existing estimates for effectiveness 21–27 days after vaccination than for longer follow-up when second dose coverage varied between studies. However, a study based in Scotland where the majority received only single dose BNT162b estimated 87% (70 to 94) effectiveness against hospitalisation in those aged 80 and over at an equivalent time point (35–41 days post vaccination) [7], suggesting that differences in second dose coverage may not explain the differences between estimated effectiveness.

Finally, an important consideration in observational studies is bias in selection into the intervention group. While all existing studies used statistical methods to adjust for biases [5, 7, 8, 21], we exploited the precise age thresholds that determined temporal eligibility for vaccination, thereby reducing the risk of unmeasured confounding between cases and controls. Such biases are exacerbated with longer follow-up periods as those remaining unvaccinated become increasingly different from those vaccinated earlier. The divergence between our effectiveness estimates and those in other studies with longer follow-up may reflect less bias in our study design and adjustment methodology.

We focused on older people at high risk of serious COVID-19 outcomes. We considered a period and country experiencing widespread transmission and large numbers of hospitalisations. This provided statistical precision in the effectiveness estimates within a short period. We exploited a precise age cut-off that determined access to the vaccine, which reduced bias from selection into treatment.

Nonetheless, there is a risk of bias from unmeasured confounding with any observational study. We matched cases and controls on combinations of 12 personal, household and area variables. We also compared four measures of hospital use in the previous 18 months and history of negative SARS-CoV-2 tests (see Appendix 5). Vaccinated individuals did not have lower event rates and had higher use of hospital services and more community-based COVID-19 tests prior to vaccination when compared to the control group. This likely reflects the age difference which may bias our estimates towards lower than true effectiveness.

The rich set of matching variables meant some cases were excluded because there was no control available. These exclusions were more likely for some populations, including minority ethnic groups and residents of London, but the included individuals had similar outcomes to the excluded individuals and the effectiveness results were similar when we matched on fewer variables (Appendix 4).

The speed of the rollout of the NHS vaccination programme in England into younger populations reduced the pool of similar people who had not been vaccinated. We adjusted for the selection bias this generated and assessed the robustness of this adjustment by comparing to a younger age group where the selection bias occurred later in the monitoring period.

Finally, we considered COVID-19 related hospitalisations as well as positive COVID-19 tests. Hospitalisations are less likely to be influenced by changes in attitudes after receiving a vaccine that may affect whether individuals seek COVID-19 tests, such as misperceptions of immunity or misinterpretations of symptoms as side effects.


We provide evidence of high real-world effectiveness of the original dosing schedule of the BNT162b2 mRNA COVID-19 vaccine in preventing infections and hospitalisations despite the widespread transmission of the B.1.1.7 variant shortly after the study population was vaccinated. There have been concerns about reduced vaccine effectiveness, though our data is consistent with mass vaccination data [5, 7, 8] and only slightly reduced neutralisation of B.1.1.7 pseudovirus relative to the Wuhan reference strain [22].

Our study provides rigorous evidence to support effectiveness of vaccination in the real-world amongst older people. Future research priorities include the optimal dosing regimen, the longevity of this protection and applicability to other variants, effectiveness amongst younger people and specific population subgroups, and effects on onward transmission and asymptomatic infection.

Availability of data and materials

Data used in the study are not publicly available and may be obtained via NHS Digital ( The analysis scripts used for the evaluation are available at



Accident and Emergency (also known as Emergency Department)


Admitted Patient Care Commissioning Dataset


Black, Asian and minority ethnic


BioNTech 162b2 [vaccine]


Control of patient information


Coronavirus disease 2019


Emergency Care Dataset


Emergency department


Financial Year


International Classification of Diseases 10th Revision


International Committee of Medical Journal Editors


Indices of multiple deprivation


Master Patient Index


Messenger ribonucleic acid


Middle layer super output area


National Health Application and Infrastructure Services


National Health Service


National Institute for Health Research


National Immunisation Management Service


Office for National Statistics


Polymerase chain reaction


Severe acute respiratory syndrome coronavirus 2


Systematized Nomenclature of Medicine Clinical Terms


Strengthening The Reporting of OBservational Studies in Epidemiology


  1. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384:403–16.

    Article  CAS  Google Scholar 

  2. Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99–111.

    Article  CAS  Google Scholar 

  3. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383:2603–15.

    Article  CAS  Google Scholar 

  4. Mahase E. COVID-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant. BMJ. 2021;372:2021.

    Article  Google Scholar 

  5. Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA COVID-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;384:1412–23.

  6. Public Health England. Investigation of novel SARS-COV-2 variant: variant of concern 202012/01. 2020

    Google Scholar 

  7. Vasileiou E, Simpson CR, Shi T, et al. Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. Lancet. 2021;397(10285):1646–57.

  8. Bernal JL, Andrews N, Gower C, et al. Early effectiveness of COVID-19 vaccination with BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on symptomatic disease, hospitalisations and mortality in older adults in the UK: a test negative case control study. medRxiv. 2021;

  9. Hall VJ, Foulkes S, Saei A et al. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. Lancet. 2021;397(10286):1725–35.

  10. Joint Committee on Vaccination and Immunisation. Advice on priority groups for COVID-19 vaccination. 2020. (accessed March 11, 2021).

    Google Scholar 

  11. Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584:430–6.

    Article  CAS  Google Scholar 

  12. Boraschi D, Aguado MT, Dutel C, et al. The gracefully aging immune system. Sci Transl Med. 2013;5:1–10.

    Article  Google Scholar 

  13. Stuart EA. Matching methods for causal inference: a review and a look forward. Stat Sci. 2010;25:1–21.

    Article  Google Scholar 

  14. NHS. Middle Layer Super Output Area definition. NHS Data Model Dict. (accessed March 11, 2021).

  15. Ministry of Housing Communities & Local Government. National Statistics: English indices of deprivation 2019. 2019. (accessed March 11, 2021).

    Google Scholar 

  16. Grifoni A, Weiskopf D, Ramirez SI, et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. 2020;181:1489–1501.e15.

    Article  CAS  Google Scholar 

  17. Wajnberg A, Amanat F, Firpo A, et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science (80- ). 2020;370:1227–30.

    Article  CAS  Google Scholar 

  18. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61:344–9.

    Article  Google Scholar 

  19. Office of National Statistics (ONS). Coronavirus (COVID-19) Infection Survey, UK: 12 March 2021. 2021. (accessed March 11, 2021).

    Google Scholar 

  20. NHS England. COVID-19 Hospital Activity. 2021. (accessed March 11, 2021).

    Google Scholar 

  21. Kow CS, Hasan SS. Real-world effectiveness of BNT162b2 mRNA vaccine: a meta-analysis of large observational studies. Inflammopharmacology. 2021;29:1075–90.

    Article  CAS  Google Scholar 

  22. Muik A, Wallisch A-K, Sanger B, et al. Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera. Science (80- ). 2021;6105.

Download references


We would like to acknowledge NHS England, Arden and GEM Commissioning Support Unit, NHS Digital, Public Health England, and NHS Test and Trace for their roles in developing and managing the various datasets used as part of the study. We are grateful to James Lockyer for developing the Master Patient Index and to Stephen Smith, Nathan Abbots, Chris Jones, and Natalie Talbott for their endeavours supplying the data in a form required for the analysis. We thank Kerrison Noonan for help collating the results of the study. We also thank Chris Gibbins, Rob Shaw, Seema Patel, Ed Kendall, Svetlana Batrakova, Simon Slovik, and Nick Andrews for their advice and guidance. Andrew Jackson and Adam Roberts are thanked for their continued support throughout and Jonathan Stokes is thanked for helping edit the final manuscript.

Public involvement

It was not appropriate or possible to involve patients or the public in the design, or conduct, or reporting, or dissemination plans of our research.


TM, JH, OA, and MW are funded by NHS England & NHS Improvement. RW is funded by The University of Manchester. MS is funded by the National Institute for Health Research (NIHR) Applied Research Collaboration for Greater Manchester. YL is funded by the NIHR Policy Research Programme via the Policy Research Unit in Health and Social Care Systems and Commissioning. MS is a NIHR Senior Investigator. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.

Author information

Authors and Affiliations



TM conceived the idea and wrote the first draft of the manuscript. MW, JH, and OA undertook the analysis. TM, MW, JH, MS, RW, and YL contributed to the study design and the writing of the final manuscript. All authors read and approved the final manuscript. TM is the guarantor.

The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted. TM affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.

Corresponding author

Correspondence to Thomas F. D. Mason.

Ethics declarations

Ethics approval and consent to participate

Surveillance of COVID-19 testing and vaccination is undertaken under Regulation 3 of The Health Service (Control of Patient Information) Regulations 2002 to collect confidential patient information ( under Sections 3(i) (a) to (c), 3(i)(d) (i) and (ii) and 3(3). Review by the Heath Research Authority identified no regulatory issues with this evaluation, and ethical review is not a requirement for this study.

Data analysis was facilitated under Control of patient information (COPI) notice ( Informed consent was not required for the study.

Consent for publication

The corresponding author has the right to grant on behalf of all authors and does grant on behalf of all authors, a worldwide licence to the publishers and its licensees in perpetuity, in all forms, formats, and media (whether known now or created in the future), to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or, abstracts of the contribution, (iii) create any other derivative work(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located; and (vi) licence any third party to do any or all of the above.

Competing interests

All authors have completed the ICMJE (International Committee of Medical Journal Editors) uniform disclosure form and declare the following: no support from any organisation for the submitted work, no financial relationships with any organisations that might have an interest in the submitted work in the previous 3 years, and no other relationships or activities that could appear to have influenced the submitted work. The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1: Appendix 1

: Data sources. Appendix 2: Matching and adjustment methodology: Table A2-1 - Summary of the change in the number and COVID-19 status of people available for matching to vaccinated individuals as the monitoring period used in the evaluation is extended. Figure A2-1 - Numbers of individuals testing positive for COVID-19 post vaccination with a comparison to their match pairs as a rate per 100,000 pre and post adjustment. Appendix 3: Measuring COVID-19 related emergency hospital attendances and admissions: Table A3-1 - List of clinical codes used to identify first COVID-19 related ED attendances and hospital admissions. Figure A3-1 - Delay between specimen data for a COVID-19 positive test and the associated ED (A&E) attendance. Figure A3-2 - Counts of COVID-19 related ED (A&E) attendances and admissions by method of identification, for (a) attendances, and (b) admissions. Appendix 4: Changing composition of the study population by follow-up period: Table A4-1 - Demographic and clinical characteristics of vaccinated persons and their unvaccinated controls. Appendix 5: Comparison of vaccinated and unvaccinated controls pre-vaccination programme: Table A5-1. Adjusted odds ratios generated using a logistic regression model to predict test positivity between days 14 and 41 post vaccination event for vaccinated individuals and their pairwise controls. Figure A5-1 - Comparison of the use of hospital-based services per day for the vaccinated and the unvaccinated pairwise control group. Figure A5-2 - Comparison of the number of negative COVID-19 tests by specimen date for the vaccinated group and unvaccinated control. Appendix 6: Sensitivity of outcomes to control selection: Figure A6-1 - Percentage difference in positive COVID-19 tests, ED (A&E) attendances with COVID-19, hospital admission with COVID-19 for six matching strategies by day since first vaccine dose. Table A6-1 - Comparison of estimates of the effectiveness of the BNT162b2 mRNA Covid-19 vaccine by days since vaccination for six matching strategies. References for supporting appendices

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mason, T.F., Whitston, M., Hodgson, J. et al. Effects of BNT162b2 mRNA vaccine on COVID-19 infection and hospitalisation amongst older people: matched case control study for England. BMC Med 19, 275 (2021).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: